

Anniina Färkkilä  
biträdande professor, Handledare för doktorandprogram  
Kvinnokliniken  
Kvinnokliniken  
Doctoral Programme in Integrative Life Science  
Doctoral Programme in Biomedicine  
Doctoral Programme in Clinical Research  
HUS Kvinnosjukdomar och förlossningar  
**Adresstyp: Postadress.**  
Finland  
**E-post:** anniina.farkkila@helsinki.fi



## Kvalifikationer

**Forskningsledare (Principal Investigator)**  
Tidsperiod : 10.12.2018 - \* i Clinicum

## Anställning

**biträdande professor**  
Kvinnokliniken  
Helsingfors universitet  
Finland  
1 maj 2023 → present

**Kvinnokliniken**  
Helsingfors universitet  
Finland  
8 sep. 2010 → present

**Handledare för doktorandprogram**  
Doctoral Programme in Integrative Life Science  
Helsingfors universitet  
Finland  
1 jan. 2024 → present

**Handledare för doktorandprogram**  
Doctoral Programme in Biomedicine  
Helsingfors universitet  
Finland  
1 jan. 2014 → present

**Handledare för doktorandprogram**  
Doctoral Programme in Clinical Research  
Helsingfors universitet  
Finland  
1 jan. 2014 → present

**HUS Kvinnosjukdomar och förlossningar**  
HYKS erva  
Finland  
1 jan. 2010 → present

**Postdoctoral Fellow**  
Dana Farber Canc Inst, Dana Farber Cancer Center, Harvard University

Förenta Staterna (USA)

1 apr. 2017 → present

## Publikationer

### **Tracing back primed resistance in cancer via sister cells**

Dai, J., Zheng, S., Falco, M. M., Bao, J., Eriksson, J., Pikkusaari, S., Forstén, S., Jiang, J., Wang, W., Gao, L., Perez-Villatoro, F., Dufva, O., Saeed, K., Wang, Y., Amiryousefi, A., Färkkilä, A., Mustjoki, S., Kauppi, L., Tang, J. & Vähärautio, A., 7 feb. 2024, I: Nature Communications. 15, 1, 14 s., 1158.

### **Dysregulated germinal centre reaction with expanded T follicular helper cells in APECED lymph nodes**

Hetemäki, I., Sarkkinen, J., Heikkilä, N., Drechsel, K., Mäyränpää, M. I., Färkkilä, A., Laakso, S., Mäkitie, O., Arstila, T. P. & Kekäläinen, E., 19 dec. 2023, I: Journal of Allergy and Clinical Immunology.

### **The Emerging Role of the Single-Cell and Spatial Tumor Microenvironment in High-Grade Serous Ovarian Cancer**

Launonen, I-M., Vähärautio, A. & Färkkilä, A., okt. 2023, I: Cold Spring Harbor Perspectives in Medicine. 13, 10, 9 s., a041314.

### **Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes**

Pikkusaari, S., Tumiati, M., Virtanen, A., Oikkonen, J., Li, Y., Perez-Villatoro, F., Muranen, T., Salko, M., Huhtinen, K., Kanerva, A., Koskela, H., Tapper, J., Koivisto-Korander, R., Joutsiniemi, T., Haltia, U-M., Lassus, H., Hautaniemi, S., Färkkilä, A., Hynninen, J., Hietanen, S., & 2 andraCarpen, O. & Kauppi, L., 15 aug. 2023, I: Clinical Cancer Research. 29, 16, s. 3110-3123 14 s.

### **Uusi työkalu räätälöityyn munasarjasyövän hoitoon**

Pikkusaari, S., Tumiati, M., Virtanen, A., Oikkonen, J., Li, Y., Perez-Villatoro, F., Muranen, T., Salko, M., Huhtinen, K., Kanerva, A., Koskela, H., Tapper, J., Koivisto-Korander, R., Joutsiniemi, T., Haltia, U-M., Lassus, H., Hautaniemi, S., Färkkilä, A., Hynninen, J., Hietanen, S., & 2 andraCarpen, O. & Kauppi, L., 15 aug. 2023, I: Duodecim. 139, 9, s. 760 1 s.

### **STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer**

Ding, L., Wang, Q., Martincuks, A., Kearns, M. J., Jiang, T., Lin, Z., Cheng, X., Qian, C., Xie, S., Kim, H-J., Launonen, I-M., Färkkilä, A., Roberts, T. M., Freeman, G. J., Liu, J. F., Konstantinopoulos, P. A., Matulonis, U., Yu, H. & Zhao, J. J., jan. 2023, I: Journal for Immunotherapy of Cancer. 11, 1, 15 s., e005627.

### **Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer**

Launonen, I-M., Lyytikäinen, N., Casado, J., Anttila, E. A., Szabo, A., Haltia, U-M., Jacobson, C. A., Lin, J. R., Maliga, Z., Howitt, B. E., Strickland, K. C., Santagata, S., Elias, K., D'Andrea, A. D., Konstantinopoulos, P. A., Sorger, P. K. & Färkkilä, A., dec. 2022, I: Nature Communications. 13, 1, 14 s., 835.

### **Tumor-Derived Lyso-phosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer**

Chae, C. S., Sandoval, T. A., Hwang, S. M., Park, E. S., Giovanelli, P., Awasthi, D., Salvagno, C., Emmanuelli, A., Tan, C., Chaudhary, V., Casado, J., Kossenkov, A. V., Song, M., Barrat, F. J., Holcomb, K., Romero-Sandoval, E. A., Zamarin, D., Pépin, D., D'andrea, A. D., Färkkilä, A., & 1 andraCubillos-Ruiz, J. R., 1 aug. 2022, I: Cancer Discovery. 12, 8, s. 1904-1921 18 s.

### **Analysis of Non-Relapsed and Relapsed Adult Type Granulosa Cell Tumors Suggests Stable Transcriptomes during Tumor Progression**

Andersson, N., Haltia, U-M., Färkkilä, A., Wong, S. C., Eloranta, K., Wilson, D. B., Unkila-Kallio, L., Pihlajoki, M., Kyrölähti, A. & Heikinheimo, M., feb. 2022, I: Current Issues in Molecular Biology. 44, 2, s. 686-698 13 s.

### **Munasarjasyövän immuunipuolustukselta piiloutumisen mekanismit paljastuvat**

Launonen, I-M., Lyytikäinen, N., Casado, J., Anttila, E., Szabo, A., Haltia, U-M., Jacobson, C. A., Lin, J-R., Maliga, Z., Howitt, B., Strickland, K., Santagata, S., Elias, K., D'Andrea, A., Konstantinopoulos, P., Sorger, P. & Färkkilä, A., 2022, I: Duodecim. 138, 5, s. 455 1 s.

**Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer**

Perez Villatoro, F. R., Oikkonen, J., Casado, J., Chernenko, A., Gulhan, D. C., Tumiat, M., Li, Y., Lavikka, K. A., Hietanen, S., Hynninen, J., Haltia, U-M., Tyrmi, J. S., Laivuori, H., Konstantinopoulos, P. A., Hautaniemi, S., Kauppi, L. & Färkkilä, A., 2022, I: npj precision oncology. 6, 1, 13 s., 96.

**Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation**

Duraiswamy, J., Turrini, R., Minasyan, A., Barras, D., Crespo, I., Grimm, A. J., Casado, J., Genolet, R., Benedetti, F., Wicky, A., Ioannidou, K., Castro, W., Neal, C., Moriot, A., Renaud-Tissot, S., Anstett, V., Fahr, N., Tanyi, J. L., Eiva, M. A., Jacobson, C. A., & 16 andraMontone, K. T., Westergaard, M. C. W., Svane, I. M., Kandalaf, L. E., Delorenzi, M., Sorger, P. K., Färkkilä, A., Michielin, O., Zoete, V., Carmona, S. J., Foukas, P. G., Jr, D. J. P., Rusakiewicz, S., Doucey, M-A., Laniti, D. D. & Coukos, G., 13 dec. 2021, I: Cancer Cell. 39, 12, s. 1623-+ 41 s.

**A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer**

Konstantinopoulos, P. A., da Costa, A. A. B. A., Gulhan, D., Lee, E. K., Cheng, S-C., Hendrickson, A. E. W., Kochupurakkal, B., Kolin, D. L., Kohn, E. C., Liu, J. F., Stover, E. H., Curtis, J., Tayob, N., Polak, M., Chowdhury, D., Matulonis, U. A., Färkkilä, A., D'Andrea, A. D. & Shapiro, G., 22 sep. 2021, I: Nature Communications. 12, 1, 8 s., 5574.

**Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells**

Färkkilä, A., Rodriguez, A., Oikkonen, J., Gulhan, D. C., Huy Nguyen, Dominguez, J., Ramos, S., Mills, C. E., Perez-Villatoro, F., Lazaro, J-B., Zhou, J., Clairmont, C. S., Moreau, L. A., Park, P. J., Sorger, P. K., Hautaniemi, S., Frias, S. & D'Andrea, A. D., 15 maj 2021, I: Cancer Research. 81, 10, s. 2774-2787 14 s.

**Agile workflow for interactive analysis of mass cytometry data**

Casado, J., Lehtonen, O., Rantanen, V., Kaipio, K., Pasquini, L., Häkkinen, A., Petrucci, E., Hynninen, J., Hietanen, S., Carpen, O., Biffoni, M., Färkkilä, A. & Hautaniemi, S., 1 maj 2021, I: Bioinformatics. 37, 9, s. 1263-1268 6 s.

**Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease**

Pilsworth, J. A., Cochrane, D. R., Neilson, S. J., Moussavi, B. H., Lai, D., Munzur, A. D., Senz, J., Wang, Y. K., Zareian, S., Bashashati, A., Wong, A., Keul, J., Staebler, A., van Meurs, H. S., Horlings, H. M., Kommoss, S., Kommoss, F., Oliva, E., Färkkilä, A. E. M., Gilks, B., & 1 andraHuntsman, D. G., maj 2021, I: The Journal of Pathology. Clinical Research. 7, 3, s. 243-252 10 s.

**Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro**

Crosley, P., Farkkila, A., Jenner, AL., Burlot, C., Cardinal, O., Potts, KG., Agopsowicz, K., Pihlajoki, M., Heikinheimo, M., Craig, M., Fu, YX. & Hitt, MM., maj 2021, I: International Journal of Molecular Sciences. 22, 9, 17 s., 4699.

**Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy**

Iyer, S., Zhang, S., Yucel, S., Horn, H., Smith, S. G., Reinhardt, F., Hoefsmit, E., Assatova, B., Casado, J., Meinsohn, M-C., Barrasa, M. I., Bell, G. W., Perez-Villatoro, F., Huhtinen, K., Hynninen, J., Oikkonen, J., Galhenage, P. M., Pathania, S., Hammond, P. T., Neel, B. G., & 3 andraFarkkila, A., Pepin, D. & Weinberg, R. A., feb. 2021, I: Cancer Discovery. 11, 2, s. 384-407 24 s.

**MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia**

Rodriguez, A., Zhang, K., Färkkilä, A., Filiatrault, J., Yang, C., Velazquez, M., Furutani, E., Goldman, D. C., Garcia de Teresa, B., Garza-Mayen, G., McQueen, K., Sambel, L. A., Molina, B., Torres, L., Gonzalez, M., Vadillo, E., Pelayo, R., Fleming, W. H., Grompe, M., Shimamura, A., & 5 andraHautaniemi, S., Greenberger, J., Frias, S., Parmar, K. & D'Andrea, A. D., 7 jan. 2021, I: Cell Stem Cell. 28, 1, s. 33-+ 23 s.

**Inhibition of TGF beta 1 and TGF beta 3 promotes hematopoiesis in Fanconi anemia**

Rodriguez, A., Yang, C., Furutani, E., Teresa, B. G. D., Velazquez, M., Filiatrault, J., Sambel, L. A., Phan, T., Flores-Guzman, P., Sanchez, S., Orozco, A. M., Mayani, H., Bolukbasi, O. V., Färkkilä, A., Epperly, M., Greenberger, J., Shimamura, A., Frias, S., Grompe, M., Parmar, K., & 1 andraD'Andrea, A. D., jan. 2021, I: Experimental Hematology. 93, s. 70-U53 19 s.

### **DNA-vaurioiden hyödyntäminen munasarjasyövän hoidossa**

Färkkilä, A., Launonen, I-M., Perez, F., Virtanen, A. & Lassus, H., 2021, I: Duodecim. 137, 21, s. 2287-2295 9 s.

### **PARP:n estäjät mullistavat munasarjasyövän hoidon : hoidosta eniten hyötyvät voidaan tunnistaa geneettisen testauksen avulla**

Färkkilä, A., Lassus, H. & Loukovaara, M., 2021, I: Duodecim. 137, 21, s. 2228-2230 3 s.

### **Functional Profiling of FSH and Estradiol in Ovarian Granulosa Cell Tumors**

Haltia, U-M., Pihlajoki, M., Andersson, N., Mäkinen, L., Tapper, J., Cervera, A., Horlings, H. M., Turpeinen, U., Anttonen, M., Bützow, R., Unkila-Kallio, L., Carpen, O., Wilson, D. B., Heikinheimo, M. & Färkkilä, A., apr. 2020, I: Journal of the Endocrine Society. 4, 4, 20 s., 034.

### **Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer**

Färkkilä, A., Gulhan, D. C., Casado, J., Jacobson, C. A., Nguyen, H., Kochupurakkal, B., Maliga, Z., Yapp, C., Chen, Y-A., Schapiro, D., Zhou, Y., Graham, J. R., Dezube, B. J., Munster, P., Santagata, S., Garcia, E., Rodig, S., Lako, A., Chowdhury, D., Shapiro, G., & 7 andraMatulonis, U. A., Park, P. J., Hautaniemi, S., Sorger, P. K., Swisher, E. M., D'Andrea, A. D. & Konstantinopoulos, P. A., 19 mars 2020, I: Nature Communications. 11, 1, 13 s., 1459.

### **Virtual clinical trials identify effective combination therapies in ovarian cancer**

Kozłowska, E., Vallius, T., Hynninen, J., Hietanen, S., Färkkilä, A. & Hautaniemi, S., 10 dec. 2019, I: Scientific Reports. 9, 9 s., 18678.

### **Open Source Infrastructure for Health Care Data Integration and Machine Learning Analyses**

Isoviita, V-M., Salminen, L., Azar, J., Lehtonen, R., Roering, P., Carpen, O., Hietanen, S., Grénman, S., Hynninen, J., Färkkilä, A. & Hautaniemi, S., 27 aug. 2019, I: JCO Clinical Cancer Informatics. 3, 16 s.

### **Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma**

Konstantinopoulos, P. A., Waggoner, S., Vidal, G. A., Mita, M., Moroney, J. W., Holloway, R., Van Le, L., Sachdev, J. C., Chapman-Davis, E., Colon-Otero, G., Penson, R. T., Matulonis, U. A., Kim, Y. B., Moore, K. N., Swisher, E. M., Färkkilä, A., D'Andrea, A., Stringer-Reasor, E., Wang, J., Buerstatte, N., & 5 andraArora, S., Graham, J. R., Bobilev, D., Dezube, B. J. & Munster, P., aug. 2019, I: JAMA Oncology. 5, 8, s. 1141-1149 9 s.

### **Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer**

Oikkonen, J., Zhang, K., Salminen, L., Schulman, I., Lavikka, K., Andersson, N., Ojanperä, E., Hietanen, S., Grénman, S., Lehtonen, R., Huhtinen, K., Carpen, O., Hynninen, J., Färkkilä, A. & Hautaniemi, S., 3 maj 2019, I: JCO Precision Oncology. 3, 3, s. 1-12 12 s.

### **Evaluation of risk factors for oral infection with potential for spread in a 1-year cohort study**

Färkkilä, E., Rautemaa-Richardson, R., Färkkilä, A., Grönholm, L. & Lauhio, A., feb. 2019, I: Clinical Oral Investigations. 23, 2, s. 905-911 7 s.

### **Other Primary Malignancies Among Women With Adult-Type Ovarian Granulosa Cell Tumors**

Bryk, S., Pukkala, E., Färkkilä, A., Heikinheimo, M., Unkila-Kallio, L. & Riska, A., okt. 2018, I: International Journal of Gynecological Cancer. 28, 8, s. 1529-1534 6 s.

### **A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients**

Tumiati, M., Hietanen, S., Hynninen, J., Pietilä, E., Färkkilä, A., Kaipio, K., Roering, P., Huhtinen, K., Alkods, A., Li, Y., Lehtonen, R., Erkan, E. P., Tuominen, M. M., Lehti, K., Hautaniemi, S. K., Vähärautio, A., Grenman, S., Carpen, O. & Kauppi, L., 15 sep. 2018, I: Clinical Cancer Research. 24, 18, s. 4482-4493 12 s.

### **Mathematical Modeling Predicts Response to Chemotherapy and Drug Combinations in Ovarian Cancer**

Kozłowska, E., Färkkilä, A., Vallius, T., Carpen, O., Kempainen, J., Grenman, S., Lehtonen, R., Hynninen, J., Hietanen, S. & Hautaniemi, S., 15 juli 2018, I: Cancer Research. 78, 14, s. 4036-4044 9 s.

#### **TERT promoter mutation in adult granulosa cell tumor of the ovary**

Pilsworth, J. A., Cochrane, D. R., Xia, Z., Aubert, G., Färkkilä, A. E. M., Horlings, H. M., Yanagida, S., Yang, W., Lim, J. L. P., Wang, Y. K., Bashashati, A., Keul, J., Wong, A., Norris, K., Brucker, S. Y., Taran, F.-A., Krämer, B., Staebler, A., van Meurs, H., Oliva, E., & 6 andraShah, S. P., Kommoss, S., Kommoss, F., Gilks, C. B., Baird, D. M. & Huntsman, D. G., juli 2018, I: *Modern Pathology*. 31, 7, s. 1107-1115 9 s.

#### **Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells**

Haltia, U.-M., Andersson, N., Yadav, B., Farkkila, A., Kuleskiy, E., Kankainen, M., Tang, J., Butzow, R., Riska, A., Leminen, A., Heikinheimo, M., Kallioniemi, O., Unkila-Kallio, L., Wennerberg, K., Aittokallio, T. & Anttonen, M., mars 2017, I: *Gynecologic Oncology*. 144, 3, s. 621-630 10 s.

#### **FOXL2 402C > G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor**

Farkkila, A., McConechy, M. K., Yang, W., Talhouk, A., Ng, Y., Lum, A., Morin, R. D., Bushell, K., Riska, A., McAlpine, J. N., Gilks, C. B., Unkila-Kallio, L., Anttonen, M. & Huntsman, D. G., jan. 2017, I: *Journal of Molecular Diagnostics*. 19, 1, s. 126-136 11 s.

#### **Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Mullerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors**

Haltia, U.-M., Hallamaa, M., Tapper, J., Hynninen, J., Alfthan, H., Kalra, B., Ritvos, O., Heikinheimo, M., Unkila-Kallio, L., Perheentupa, A. & Farkkila, A., jan. 2017, I: *Gynecologic Oncology*. 144, 1, s. 83-89 7 s.

#### **Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary**

Farkkila, A., Haltia, U.-M., Tapper, J., McConechy, M. K., Huntsman, D. G. & Heikinheimo, M., 2017, I: *Annals of Medicine*. 49, 5, s. 435-447 13 s.

#### **Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors**

Bryk, S. S., Färkkilä, A., Butzow, R., Leminen, A., Johanna, T., Heikinheimo, M., Unkila-Kallio, L. & Riska, A., dec. 2016, I: *Gynecologic Oncology*. 143, 3, s. 571-577 7 s.

#### **Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype**

McConechy, M. K., Farkkila, A., Horlings, H. M., Talhouk, A., Unkila-Kallio, L., van Meurs, H. S., Yang, W., Rozenberg, N., Andersson, N., Zaby, K., Bryk, S., Butzow, R., Halfwerk, J. B. G., Hooijer, G. K. J., van de Vijver, M. J., Buist, M. R., Kenter, G. G., Brucker, S. Y., Kramer, B., Staebler, A., & 6 andraBleeker, M. C. G., Heikinheimo, M., Kommoss, S., Gilks, C. B., Anttonen, M. & Huntsman, D. G., nov. 2016, I: *Journal of the National Cancer Institute*. 108, 11, 5 s., 134.

#### **Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumors-implications for therapeutic potential**

Farkkila, A., Zauli, G., Haltia, U.-M., Pihlajoki, M., Unkila-Kallio, L., Secchiero, P. & Heikinheimo, M., sep. 2016, I: *Tumor Biology*. 37, 9, s. 11909-11916 8 s.

#### **GATA factors in endocrine neoplasia**

Pihlajoki, M., Farkkila, A., Soini, T., Heikinheimo, M. & Wilson, D. B., feb. 2016, I: *Molecular and Cellular Endocrinology*. 421, C, s. 2-17 16 s.

#### **Munasarjan granuloosisolukasvaimen diagnostiikka ja seuranta tarkentuvat**

Färkkilä, A. & Unkila-Kallio, L., 2016, I: *Duodecim*. 132, 11, s. 1033-1039 7 s.

#### **Toisen raskauskolmanneksen samanaikainen kohdunulkoinen ja -sisäinen raskaus on vakava raskauskomplikaatio**

Färkkilä, A. & Laitinen, L., 2016, I: *Duodecim*. 132, 8, s. 730-733 4 s.

#### **The clinical utility of serum anti-Mullerian hormone in the follow-up of ovarian adult-type granulosa cell tumorsA comparative study with inhibin B**

Farkkila, A., Koskela, S., Bryk, S., Alfthan, H., Butzow, R., Leminen, A., Puistola, U., Tapanainen, J. S., Heikinheimo, M., Anttonen, M. & Unkila-Kallio, L., 1 okt. 2015, I: *International Journal of Cancer*. 137, 7, s. 1661-1671 11 s.

**Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience.**

Bryk, S. S., Färkkilä, A., Butzow, R., Anttonen, M., Heikinheimo, M., Leminen, A., Riska, A. & Unkila-Kallio, L., 25 jan. 2015, I: International Journal of Gynecological Cancer. 25, 1, s. 33-41 9 s.

**Sensitivity of human granulosa cell tumor cells to epidermal growth factor receptor inhibition**

Andersson, N., Anttonen, M., Farkkila, A., Pihlajoki, M., Butzow, R., Unkila-Kallio, L. & Heikinheimo, M., apr. 2014, I: Journal of Molecular Endocrinology. 52, 2, s. 223-234 12 s.

**FOXL2, GATA4, and SMAD3 Co-Operatively Modulate Gene Expression, Cell Viability and Apoptosis in Ovarian Granulosa Cell Tumor Cells**

Anttonen, M., Pihlajoki, M., Andersson, N., Georges, A., L'Hote, D., Vattulainen, S., Farkkila, A., Unkila-Kallio, L., Veitia, R. A. & Heikinheimo, M., 9 jan. 2014, I: PLoS One. 9, 1, 8 s., 85545.

**HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study**

Färkkilä, A., Andersson, N. K., Butzow, R., Leminen, A., Heikinheimo, M., Anttonen, M. & Unkila-Kallio, L., 2014, I: Cancer medicine . 3, 3, s. 526-536 11 s.

**Seerumin anti-Müllerin hormonin (AMHn) kliininen käyttö : lisääntymisestä granuloosasolukasvaimiin**

Färkkilä, A. & Anttonen, M., 2014, I: Kliin lab : kliinisen laboratorioalan julkaisu : SKKY:n jäsenlehti.. 31, 3, s. 36-39 4 s.

**Klinisk användning av serum Anti-Müllerskt Hormon (AMH): Från reproduktion till granulosacelltumörer**

Färkkilä, A. & Anttonen, M., 2012, I: Klinisk biokemi i Norden.. 24, 1, s. 50-54 5 s.

**Molecular studies on pathogenesis, prognostic factors, and new treatment options for ovarian granulosa cell tumors**

Färkkilä, A., 2012, Helsinki: [A. Färkkilä]. 80 s.

**Anti-Mullerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis**

Anttonen, M., Färkkilä, A., Tauriala, H., Kauppinen, M., MacLaughlin, D. T., Unkila-Kallio, L., Butzow, R. & Heikinheimo, M., 2011, I: Laboratory Investigation. 91, 11, s. 1605-1614 10 s.

**Serum Vascular Endothelial Growth Factor A (VEGF) Is Elevated in Patients with Ovarian Granulosa Cell Tumor (GCT), and VEGF Inhibition by Bevacizumab Induces Apoptosis in GCT in Vitro**

Farkkila, A., Pihlajoki, M., Tauriala, H., Butzow, R., Leminen, A., Unkila-Kallio, L., Heikinheimo, M. & Anttonen, M., 2011, I: Journal of Clinical Endocrinology and Metabolism. 96, 12, s. E1973-E1981 9 s.

**Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors**

Färkkilä, A., Anttonen, M. T., Pociuviene, J., Leminen, A., Butzow, R., Heikinheimo, M. & Unkila-Kallio, L., 2011, I: European Journal of Endocrinology. 164, 1, s. 115-122 8 s.

**Vascular endothelial growth factor-C accelerates diabetic wound healing**

Saaristo, A., Tammela, T., Färkkilä, A., Kärkkäinen, M., Suominen, E., Ylä-Herttua, S. & Alitalo, K., 2006, I: The American Journal of Pathology. 169, 3, s. 1080-1087 8 s.

## Priser

**Eero Saksela palkinto**

Färkkilä, Anniina (!!Recipient), 23 sep. 2022

**Seth Wichmann palkinto**

Färkkilä, Anniina (!!Recipient), 15 nov. 2018

## Projekt

### Discovery and therapeutic exploitation of immunological vulnerabilities in high grade serous ovarian cancer

Färkkilä, A.  
01/01/2019 → ...

### Discovery and therapeutic exploitation of immunological vulnerabilities in ovarian cancer

Färkkilä, A., Kang, Z., Niemiec, I., Nagaraj, A., Perez Villatoro, F. R., Chernenko, A. & Shah, S.  
01/01/2021 → 31/12/2023

### Discovery and therapeutic exploitation of immunological vulnerabilities in ovarian cancer

Färkkilä, A., Casado, J., Perez Villatoro, F. R., Pietilä, E., Nagaraj, A. & Launonen, I. P.  
SUOMEN AKATEMIA  
01/01/2021 → 31/12/2024

### EU\_ERC\_Färkkilä Anniina\_Space\_101076096

Färkkilä, A., Chernenko, A., Hincapie Otero, M. M., Kang, Z., Niemiec, I. & Shah, S.  
European Commission Joint Research Centre  
01/02/2023 → 31/01/2028

### Munasarjasyöväen täsmälääketiede immunogenomisen profiiloinnin avulla

Färkkilä, A. & Nagaraj, A.  
Suomen Akatemia Projektilaskutus  
01/09/2022 → 31/08/2026

### Syöpäsäätiö 2024-26\_Färkkilä

Färkkilä, A.  
Syöpäsäätiö sr Cancerstiftelsen sr  
01/01/2024 → 31/12/2026

SELECTED INTERNATIONAL INVITED TALKS 09/2021AACR Virtual special conference: Ovarian cancer 2021  
04/2021University of Minnesota Department of Pharmacology Spring seminar 2021 (virtual) 03/2021Annual meeting 2021, NSGO, Copenhagen, Denmark (virtual) 06/2020Ludwig meeting, The Ludwig Center of Harvard Medical School, Boston, USA 01/2020Annual meeting, Stand Up to Cancer, Santa Monica, CA, USA 11/2019Annual meeting 2019, Mexican society of Human Genetics, Tuxtla, Chiapas, Mexico 06/2019Annual meeting 2019, British Society for Gynecologic Oncology, Cambridge, UK 06/2016Annual meeting 2016, Nordic Federation of Obstetrics and Gynecologists, Helsinki, Finland ORGANISATION OF SCIENTIFIC MEETINGS (as a Coordinator) 23.08.2021Special seminar on Highly Multiplexed imaging and Spatial proteomics, UH and HUH 2019 - Bioimaging Informatics working group, monthly seminars, ONCOSYS Research Program, HUH 18.11.2020Advances in the treatment of Gynecologic cancers 2020, Virtual Symposium, UH and HUH 18.11.2019Biomedicum Helsinki invited lecturer Professor David Huntsman, Vancouver, BC, Canada 26.08.2019Advances in Precision Oncology and Biomarkers in Clinical Trials Symposium, UH and HUH 26.01.2017Clinical data- workshop, Hercules EU consortium INSTITUTIONAL RESPONSIBILITIES 2021-Student mentor for MD-PhD program, UH, Finland 09/2021Official PhD Opponent, University of Bergen, Norway 2022Thesis committee, Santeri Pekola, B.Med 2021Thesis committee, Essi Friman, MD 2020Thesis committee, Michaela Feodoroff, M.Sc 2020Thesis committee, Wafa Wahbi, M.Sc 2020Thesis committee, Petra Nygren, B.Med 2019Thesis committee, Sara Khamaiseh, M.Sc 2016Pre-examiner, Susanna Jonkka M.Sc, Master's Thesis 2016 - 2020Thesis committee, Liina Salminen MD 2015Thesis committee, Jaana Tolvanen M.Sc 2015Thesis committee, Elina Pietilä M.Sc 2016Pre-examiner, Susanna Jonkka M.Sc, Master's Thesis, UH, Finland EXPERT PANELS AND REVIEWING ACTIVITY 2021 - Board member, European Network of gynecological clinical trials (ENTOG) and Gynecologic Cancer Inter Group (GCIG) 2021 - Board member, Finnish Cancer Center (FICAN) National Molecular tumor board 2021 - Board member, GSK Advisory Board "Evolving Role of Homologous Recombination Deficiency (HRD) Testing in the Treatment of Ovarian Cancer" 2020 - Board member, Translational working group, Nordic Society for Gynecologic Oncology (NSGO) Clinical trials unit 2020 - Consortium member, Nordic consortium for HRD biomarker development 2020Review panel member, National Autonomous University of Mexico, Mexico 2019 - Board member, Ethical board, Helsinki University Hospital, Helsinki, Finland 2015- Reviewer for 15 scientific journals such as Nature, Annals of Oncology Nature Communications, Cancer Research, International Journal of Cancer, Gynecologic Oncology, Cancers MAJOR COLLABORATIONS George Coukos Functional states of tumor-infiltrating lymphocytes in high-grade serous ovarian cancer. University of Lausanne, Lausanne, Switzerland Robert WeinbergImmune microenvironments and therapeutic vulnerabilities of novel syngeneic mouse models of ovarian cancer. Whitehead Institute, Boston, MA, USA David HuntsmanMolecular diagnostics of ovarian

granulosa cell tumors. University of British Columbia, Vancouver, BC, Canada CAREER BREAKS 01.12.2009 - 31.8.2010 Maternity leave (9 months) 10.08.2012 - 31.4.2013 Maternity leave (9 months)